Dept. of Obstetrics and Gynecology (산부인과학교실)

Researcher List

Keyword Cloud

Journal Categories

Highly Cited Articles

MicroRNA expression profiles in serous ovarian carcinoma

Eun Ji Nam ; Heejei Yoon ; Sang Wun Kim ; Hoguen Kim ; Young Tae Kim ; Jae Ho... CLINICAL CANCER RESEARCH, Vol.14(9) : 2690-2695, 2008
PDF

Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial o...

HanByoul Cho ; Hye Won Hur ; Sang Wun Kim ; Sung Hoon Kim ; Jae Hoon Kim ; Yo... CANCER IMMUNOLOGY IMMUNOTHERAPY, Vol.58(1) : 15-23, 2009

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expr...

Funda Meric-Bernstam ; Vicky Makker ; Ana Oaknin ; Do-Youn Oh ; Susana Banerj... JOURNAL OF CLINICAL ONCOLOGY, Vol.42(1) : 47-58, 2024-01
PDF
This table browses all dspace content
Issue DateTitleJournal Title
2024Reply to: Comments on "Randomized, two-arm, non-comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045INTERNATIONAL JOURNAL OF CANCER
2024Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial JOURNAL OF CLINICAL ONCOLOGY
2024Development and validation of artificial intelligence-based analysis software to support screening system of cervical intraepithelial neoplasia SCIENTIFIC REPORTS
2024Effects of hormone replacement therapy on bone mineral density in Korean adults With Turner syndrome JOURNAL OF KOREAN MEDICAL SCIENCE
2024Clinical guidelines for ovarian cancer: the Korean Society of Gynecologic Oncology guidelines JOURNAL OF GYNECOLOGIC ONCOLOGY
2024Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial JOURNAL OF CLINICAL ONCOLOGY
2024Lugol's Solution Reduces Positive Margins and Residual Disease After the Large Loop Excision of Transformation ZoneJOURNAL OF LOWER GENITAL TRACT DISEASE
2024Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study CLINICAL CANCER RESEARCH
2023Secondary cytoreductive surgery with and without hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer GLAND SURGERY
2023Tibolone and Breast Cancer Journal of Menopausal Medicine
2023Extrauterine Undifferentiated Uterine Sarcoma Arising from Bladder Endometriosis in a Postmenopausal Woman: A Case Report Journal of Menopausal Medicine
2023Randomized, two-arm, noncomparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045INTERNATIONAL JOURNAL OF CANCER
2023Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trialLANCET ONCOLOGY
2023Personal exposure of PM2.5 and metabolic syndrome markers of pregnant women in South Korea: APPO study ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH
2023Initial experience with the da Vinci SP robot-assisted surgical staging of endometrial cancer: a retrospective comparison with conventional laparotomyJOURNAL OF ROBOTIC SURGERY
2023Hepatic stellate cells activate and avoid death under necroptosis stimuli: Hepatic fibrosis during necroptosisJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
2023Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian CancerNEW ENGLAND JOURNAL OF MEDICINE
2023Genomic hypomethylation in cell-free DNA predicts responses to checkpoint blockade in lung and breast cancer SCIENTIFIC REPORTS
2023Cystic Degeneration of Uterine Fibroid Mimicking Heterotopic Pregnancy with Interstitial Pregnancy: A Case Report Perinatology
2023Globally shared TCR repertoires within the tumor-infiltrating lymphocytes of patients with metastatic gynecologic cancer SCIENTIFIC REPORTS

Browse

Links